Burning Rock Biotech (NASDAQ:BNR) Raised to Hold at Zacks Investment Research

Burning Rock Biotech (NASDAQ:BNRGet Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Burning Rock Biotech Limited focuses on the application of next generation sequencing technology in the field of precision oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients as well as NGS-based cancer early detection. Burning Rock Biotech Limited is based in GUANGZHOU, China. “

BNR traded down $0.34 during midday trading on Tuesday, hitting $2.66. 275,555 shares of the company traded hands, compared to its average volume of 302,140. The company’s 50-day moving average is $6.94 and its 200 day moving average is $9.17. Burning Rock Biotech has a 52 week low of $2.63 and a 52 week high of $34.71. The firm has a market capitalization of $279.59 million, a PE ratio of -2.25 and a beta of -0.33.

Burning Rock Biotech (NASDAQ:BNRGet Rating) last issued its quarterly earnings data on Monday, March 21st. The company reported ($0.38) earnings per share for the quarter. The business had revenue of $23.12 million during the quarter. Burning Rock Biotech had a negative return on equity of 37.96% and a negative net margin of 156.90%. During the same quarter in the previous year, the business earned ($0.23) EPS. On average, analysts expect that Burning Rock Biotech will post -0.93 EPS for the current year.

Several hedge funds have recently bought and sold shares of BNR. Jane Street Group LLC bought a new stake in Burning Rock Biotech in the first quarter worth $97,000. State Street Corp lifted its position in shares of Burning Rock Biotech by 12.9% during the first quarter. State Street Corp now owns 196,590 shares of the company’s stock worth $1,826,000 after purchasing an additional 22,457 shares during the last quarter. Invesco Ltd. increased its stake in shares of Burning Rock Biotech by 60.3% during the first quarter. Invesco Ltd. now owns 60,609 shares of the company’s stock valued at $563,000 after buying an additional 22,805 shares during the period. Vanguard Group Inc. increased its stake in shares of Burning Rock Biotech by 2.6% during the first quarter. Vanguard Group Inc. now owns 1,053,368 shares of the company’s stock valued at $9,786,000 after buying an additional 26,289 shares during the period. Finally, Kynam Capital Management LP increased its stake in shares of Burning Rock Biotech by 102.1% during the first quarter. Kynam Capital Management LP now owns 773,114 shares of the company’s stock valued at $7,182,000 after buying an additional 390,650 shares during the period. 45.05% of the stock is owned by hedge funds and other institutional investors.

Burning Rock Biotech Company Profile (Get Rating)

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Read More

Get a free copy of the Zacks research report on Burning Rock Biotech (BNR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.